Oral and IV Dosages of Doxorubicin-Methotrexate loaded-Nanoparticles Inhibit Progression of Oral Cancer by Down-Regulation of Matrix Methaloproteinase 2 Expression in Vivo

• DOI: 10.7314/apjcp.2014.15.24.10705
• Publication Date: 2015-03-03T03:53:20Z
• Authors: Mehran Mesgari Ab...; Rana Jahanban-Esf...; Amir Monfaredan; Khaled Seidi; Hamed Hamishehkar; Monir Moradzadeh ...
• Keywords: Dose; Matrix (chemical analysis)

Oral cancer is one of the most common and lethal cancers in world. Combination chemotherapy coupled with nanoparticle drug delivery holds substantial promise therapy. This study aimed to evaluate efficacy safety two dosages our novel pH temperature sensitive doxorubicin-methotrexate-loaded nanoparticles (DOX-MTX NPs) attention MMP-2 mRNA profile a 4-nitroquinoline-1-oxide induced oral squamous cell carcinoma (OSCC) model rat. Our results showed that both IV DOX-MTX NP caused significant decrease levels compared untreated group (p<0.003). Surprisingly, was not affected DOX treated (p>0.05). indicated dosage MTX-DOX more effective than free (12 fold) inhibiting activity OSCCs (P<0.001). Furthermore, expression relation histopathological changes (P=0.011). Compared group, we observed no pathological neither alteration amount either healthy controls were NPs whilst high level (p<0.001).Taking together indicate DOX- MTX safe chemotherapeutic nanodrug its forms possess potent anti-cancer properties on aggressive tumors like OSCC, possibly by affecting genes drive tumor invasion metastasis.